Study evaluation of 2nd hormone line response by -[18F]fluoro-17ß-œstradiol (FES) PET/CT in metastatic breast cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-002120-83-FR

Enrollment

Registered

2017-01-05

Start date

2016-10-05

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 19.0 Level: LLT Classification code 10007305 Term: Carcinoma breast System Organ Class: 100000004864

Interventions

Product Name: [18F]fluoro-17ß-œstradiol Product Code: FES Pharmaceutical Form: Solution for injection/infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactDRCI

INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU

drci@ico.unicancer.fr33240 67 99 00 9168

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026